GlassScriptPhysician profile
Cristin E Blaney
NPI 1992165526
$1,748.70
in general payments reported to CMS, 2019-2025
20 companies · $100 in 2025
The $100 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $129 · 2023: $98.41 · 2024: $1,421 · 2025: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,434 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,434.36 |
| Education | $184.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $278.17 | 2024 | Vtama |
| Abbvie INC. | $256.45 | 2023-2025 | |
| Genzyme Corporation | $177.31 | 2024 | |
| Janssen Biotech, INC. | $174.20 | 2023-2024 | Tremfya |
| Boston Scientific Corporation | $129.36 | 2021 | |
| Sun Pharmaceutical Industries INC. | $122.74 | 2023-2024 | Absorica Ld, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $88.08 | 2024 | Sotyktu |
| Lilly USA, LLC | $80.28 | 2024 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $72.33 | 2024 | |
| Leo Pharma INC. | $63.65 | 2024 | Adbry |
| Incyte Corporation | $49.94 | 2024 | Opzelura |
| Amgen INC. | $45.44 | 2024 | Otezla |
| Kyowa Kirin, INC. | $41.31 | 2023 | Poteligeo |
| Regeneron Healthcare Solutions, INC. | $41.05 | 2024 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.05 | 2024 | Spevigo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $31.30 | 2024 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $23.11 | 2024 | |
| Galderma Laboratories, L.P. | $14.77 | 2024 | |
| Verrica Pharmaceuticals INC. | $13.73 | 2024 | Ycanth |
| Arcutis Biotherapeutics, INC. | $13.43 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cristin Blaney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.